NIKKEI 225
39,038.16 +354.23 (+0.92%) HANG SENG
18,366.95 -109.85 (-0.59%) CRUDE OIL
78.11 +0.37 (+0.48%) GOLD FUTURES
2,328.20 +1.20 (+0.05%) DOW
38,868.04 +69.05 (+0.18%) Bitcoin GBP
54,521.84 -170.65 (-0.31%)
BMY Aug 2024 35.000 put
- Simply Wall St.
Bristol-Myers Squibb Insiders Sold US$1.1m Of Shares Suggesting Hesitancy
Over the past year, many Bristol-Myers Squibb Company ( NYSE:BMY ) insiders sold a significant stake in the company...
- Benzinga
FDA Approves Geron's First Commercial Drug, Competes With Bristol Myers Squibb's Blood Cancer Drug
On Thursday, the FDA approved Geron Corporation's (NASDAQ:GERN) Rytelo (imetelstat) for adult patients with low-to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia. The approval covers patients requiring four or more red blood cell units over eight weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents. In March, by a 12-to-2 margin, the FDA adcomm panel voted in favor of the benefits of imetelstat, st
- Insider Monkey
Here’s Why Jim Cramer Says You Should Not Buy Bristol-Myers Squibb Co (NYSE:BMY)
We recently published the list of 11 stocks Jim Cramer is bearish on. Bristol-Myers Squibb Co (NYSE:BMY) ranks 2nd in the list. Click to see the full list of 11 stocks Cramer is bearish on. In this article we will take a deeper look at BMY and find out whether Cramer’s thesis holds any weight. […]
